Hematopoietic cell transplantation for primary plasma cell leukemia

Results from the Center for International Blood and Marrow Transplant Research

A. Mahindra, M. E. Kalaycio, J. Vela-Ojeda, D. H. Vesole, M. J. Zhang, P. Li, J. R. Berenson, J. M. Bird, A. Dispenzieri, J. L. Gajewski, R. P. Gale, L. Holmberg, S. Kumar, R. A. Kyle, H. M. Lazarus, S. Lonial, J. Mikhael, G. A. Milone, R. Munker, R. Nath & 5 others S. Saccaro, L. B. To, D. T. Vogl, B. Wirk, P. Hari

    Research output: Contribution to journalArticle

    45 Citations (Scopus)

    Abstract

    There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34% (95% confidence interval (CI), 23-46%) in the autologous group and 20% (95% CI, 10-34%) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61% (95% CI, 48-72%) in the autologous group and 38% (95% CI, 25-53%) in the allogeneic group. Overall survival (OS) at 3 years was 64% (95% CI, 52-75%) in the autologous group and 39% (95% CI, 26-54%) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5% (95% CI, 1-11%) in the autologous group and 41% (95% CI, 28-56%) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.

    Original languageEnglish (US)
    Pages (from-to)1091-1097
    Number of pages7
    JournalLeukemia
    Volume26
    Issue number5
    DOIs
    StatePublished - May 2012

    Fingerprint

    Plasma Cell Leukemia
    Cell Transplantation
    Bone Marrow
    Confidence Intervals
    Transplants
    Research
    Survival
    Recurrence
    Mortality
    Plasma Cells
    Disease-Free Survival
    Safety

    Keywords

    • overall survival
    • Primary plasma cell leukemia
    • stem cell transplant

    ASJC Scopus subject areas

    • Hematology
    • Cancer Research
    • Anesthesiology and Pain Medicine

    Cite this

    Hematopoietic cell transplantation for primary plasma cell leukemia : Results from the Center for International Blood and Marrow Transplant Research. / Mahindra, A.; Kalaycio, M. E.; Vela-Ojeda, J.; Vesole, D. H.; Zhang, M. J.; Li, P.; Berenson, J. R.; Bird, J. M.; Dispenzieri, A.; Gajewski, J. L.; Gale, R. P.; Holmberg, L.; Kumar, S.; Kyle, R. A.; Lazarus, H. M.; Lonial, S.; Mikhael, J.; Milone, G. A.; Munker, R.; Nath, R.; Saccaro, S.; To, L. B.; Vogl, D. T.; Wirk, B.; Hari, P.

    In: Leukemia, Vol. 26, No. 5, 05.2012, p. 1091-1097.

    Research output: Contribution to journalArticle

    Mahindra, A, Kalaycio, ME, Vela-Ojeda, J, Vesole, DH, Zhang, MJ, Li, P, Berenson, JR, Bird, JM, Dispenzieri, A, Gajewski, JL, Gale, RP, Holmberg, L, Kumar, S, Kyle, RA, Lazarus, HM, Lonial, S, Mikhael, J, Milone, GA, Munker, R, Nath, R, Saccaro, S, To, LB, Vogl, DT, Wirk, B & Hari, P 2012, 'Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research', Leukemia, vol. 26, no. 5, pp. 1091-1097. https://doi.org/10.1038/leu.2011.312
    Mahindra, A. ; Kalaycio, M. E. ; Vela-Ojeda, J. ; Vesole, D. H. ; Zhang, M. J. ; Li, P. ; Berenson, J. R. ; Bird, J. M. ; Dispenzieri, A. ; Gajewski, J. L. ; Gale, R. P. ; Holmberg, L. ; Kumar, S. ; Kyle, R. A. ; Lazarus, H. M. ; Lonial, S. ; Mikhael, J. ; Milone, G. A. ; Munker, R. ; Nath, R. ; Saccaro, S. ; To, L. B. ; Vogl, D. T. ; Wirk, B. ; Hari, P. / Hematopoietic cell transplantation for primary plasma cell leukemia : Results from the Center for International Blood and Marrow Transplant Research. In: Leukemia. 2012 ; Vol. 26, No. 5. pp. 1091-1097.
    @article{46d66096fd164ce39d1ae9afa74b4394,
    title = "Hematopoietic cell transplantation for primary plasma cell leukemia: Results from the Center for International Blood and Marrow Transplant Research",
    abstract = "There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34{\%} (95{\%} confidence interval (CI), 23-46{\%}) in the autologous group and 20{\%} (95{\%} CI, 10-34{\%}) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61{\%} (95{\%} CI, 48-72{\%}) in the autologous group and 38{\%} (95{\%} CI, 25-53{\%}) in the allogeneic group. Overall survival (OS) at 3 years was 64{\%} (95{\%} CI, 52-75{\%}) in the autologous group and 39{\%} (95{\%} CI, 26-54{\%}) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5{\%} (95{\%} CI, 1-11{\%}) in the autologous group and 41{\%} (95{\%} CI, 28-56{\%}) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.",
    keywords = "overall survival, Primary plasma cell leukemia, stem cell transplant",
    author = "A. Mahindra and Kalaycio, {M. E.} and J. Vela-Ojeda and Vesole, {D. H.} and Zhang, {M. J.} and P. Li and Berenson, {J. R.} and Bird, {J. M.} and A. Dispenzieri and Gajewski, {J. L.} and Gale, {R. P.} and L. Holmberg and S. Kumar and Kyle, {R. A.} and Lazarus, {H. M.} and S. Lonial and J. Mikhael and Milone, {G. A.} and R. Munker and R. Nath and S. Saccaro and To, {L. B.} and Vogl, {D. T.} and B. Wirk and P. Hari",
    year = "2012",
    month = "5",
    doi = "10.1038/leu.2011.312",
    language = "English (US)",
    volume = "26",
    pages = "1091--1097",
    journal = "Leukemia",
    issn = "0887-6924",
    publisher = "Nature Publishing Group",
    number = "5",

    }

    TY - JOUR

    T1 - Hematopoietic cell transplantation for primary plasma cell leukemia

    T2 - Results from the Center for International Blood and Marrow Transplant Research

    AU - Mahindra, A.

    AU - Kalaycio, M. E.

    AU - Vela-Ojeda, J.

    AU - Vesole, D. H.

    AU - Zhang, M. J.

    AU - Li, P.

    AU - Berenson, J. R.

    AU - Bird, J. M.

    AU - Dispenzieri, A.

    AU - Gajewski, J. L.

    AU - Gale, R. P.

    AU - Holmberg, L.

    AU - Kumar, S.

    AU - Kyle, R. A.

    AU - Lazarus, H. M.

    AU - Lonial, S.

    AU - Mikhael, J.

    AU - Milone, G. A.

    AU - Munker, R.

    AU - Nath, R.

    AU - Saccaro, S.

    AU - To, L. B.

    AU - Vogl, D. T.

    AU - Wirk, B.

    AU - Hari, P.

    PY - 2012/5

    Y1 - 2012/5

    N2 - There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34% (95% confidence interval (CI), 23-46%) in the autologous group and 20% (95% CI, 10-34%) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61% (95% CI, 48-72%) in the autologous group and 38% (95% CI, 25-53%) in the allogeneic group. Overall survival (OS) at 3 years was 64% (95% CI, 52-75%) in the autologous group and 39% (95% CI, 26-54%) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5% (95% CI, 1-11%) in the autologous group and 41% (95% CI, 28-56%) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.

    AB - There are limited data on hematopoietic cell transplantation (HCT) in primary plasma cell leukemia (pPCL), an aggressive plasma cell disorder. We report outcomes of 147 patients with pPCL receiving autologous (n97) or allogeneic (n50) HCT within 18 months after diagnosis between 1995 and 2006. Median age was 56 years and 48 years for autologous HCT and allogeneic HCT, respectively. Progression-free survival (PFS) at 3 years was 34% (95% confidence interval (CI), 23-46%) in the autologous group and 20% (95% CI, 10-34%) in the allogeneic group. Cumulative incidence of relapse at 3 years was 61% (95% CI, 48-72%) in the autologous group and 38% (95% CI, 25-53%) in the allogeneic group. Overall survival (OS) at 3 years was 64% (95% CI, 52-75%) in the autologous group and 39% (95% CI, 26-54%) in the allogeneic group. Non-relapse mortality (NRM) at 3 years was 5% (95% CI, 1-11%) in the autologous group and 41% (95% CI, 28-56%) in the allogeneic group. The encouraging OS after autologous HCT, establishes the safety and feasibility of this consolidative treatment option after initial induction therapy for pPCL. Allogeneic HCT, although associated with a significantly lower relapse rate, carries a much higher risk of NRM and no OS benefit.

    KW - overall survival

    KW - Primary plasma cell leukemia

    KW - stem cell transplant

    UR - http://www.scopus.com/inward/record.url?scp=84860778432&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84860778432&partnerID=8YFLogxK

    U2 - 10.1038/leu.2011.312

    DO - 10.1038/leu.2011.312

    M3 - Article

    VL - 26

    SP - 1091

    EP - 1097

    JO - Leukemia

    JF - Leukemia

    SN - 0887-6924

    IS - 5

    ER -